Abstract
Osteoporosis is a disease in which the density and quality of bone is reduced, leading to an increase in fragility fractures. Osteoporosis is a major health threat affecting more than 10 million people in Japan. Emerging evidence has shown that anti-resorptive drugs such as bisphosphonates and raloxifene efficiently increase bone mass and prevent osteoporotic fractures by maintaining bone homeostasis. In addition, anabolic drugs such as parathyroid hormone and novel anti-resorptive drugs such as anti-RANKL drugs and cathepsin K inhibitors, which directly target osteoclasts are under development. In this review, we would like to summarize the current status of the development of anti-osteoporotic drugs.
MeSH terms
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bone Density Conservation Agents*
-
Cathepsin K
-
Cathepsins / antagonists & inhibitors
-
Denosumab
-
Diphosphonates*
-
Drug Design*
-
Humans
-
Ibandronic Acid
-
Imidazoles
-
Organometallic Compounds
-
Osteoporosis / drug therapy*
-
Osteoprotegerin
-
RANK Ligand / immunology
-
Selective Estrogen Receptor Modulators*
-
Teriparatide
-
Thiophenes
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bone Density Conservation Agents
-
Diphosphonates
-
Imidazoles
-
Organometallic Compounds
-
Osteoprotegerin
-
RANK Ligand
-
Selective Estrogen Receptor Modulators
-
Thiophenes
-
strontium ranelate
-
Teriparatide
-
YM 529
-
Denosumab
-
Cathepsins
-
CTSK protein, human
-
Cathepsin K
-
Ibandronic Acid